<DOC>
	<DOCNO>NCT02339350</DOCNO>
	<brief_summary>Treatment pediatric acute lymphoblastic leukemia ( ALL ) advance overall survival exceed 80 % nowadays . However overall survival high risk ALL remain 75-90 % , thus recent study focus treatment intensification accord risk group . According previous report , design multicenter prospective trial pediatric ALL .</brief_summary>
	<brief_title>Treatment Newly Diagnosed High Risk Acute Lymphoblastic Leukemia Children</brief_title>
	<detailed_description>Purpose study 1 . For slow early responder ( SER ) , confirm augment interim maintenance use intravenous high dose methotrexate improve treatment outcome . 2 . For slow early responder ( SER ) , confirm removal prophylactic radiotherapy relieve long term complication . 3 . To predict treatment response prognosis high risk pediatric ALL monitoring minimal residual disease ( MRD ) . Inclusion criteria 1 . Diagnosis 1 . Newly diagnose B-precursor ALL meeting criterion 1.2 2 . Newly diagnose B-precursor ALL previously treat steroid . 3 . Newly diagnose T cell ALL , exclude early T-cell precursor ( ETP ) leukemia 1.2 Initial WBC count 1. 1 year old 9 year old : WBC ≥ 50,000/μL 2. 10 year old 21 year old : Any WBC 3. 1 year old 21 year old : Any WBC Testicular leukemia CNS leukemia ( CNS3 ) Exclusion criterion ( classify high risk group ) 2.1 Philadelphia chromosome ( + ) bcr/abl rearrangement ( + ) 2.2 Chromosome &lt; 45 cytogenetics 2.3 Induction failure ( Day 28 M3 marrow ( &gt; 25 % blast ) ) 2.4 ( 4:11 ) ( identify cytogenetics , FISH molecular study ) 2.5 Early T-cell precursor leukemia 2.6 Down syndrome ALL Methods We classify patient rapid early responder ( RER ) slow early responder ( SER ) , accord treatment response induction remission risk factor diagnosis . SER include M2 ( 5-25 % leukemic cell bone marrow exam ) M3 ( 25 % leukemic cell bone marrow exam ) response 14th day start induction remission . If patient show total WBC count ≥ 100,000/μL , testis CNS ( CNS 3 ) involvement diagnosis diagnose T-ALL , patient also include SER group . Rapid early responder undergo interim maintenance two time reinduction one time . Slow early responder undergo two time interim maintenance treatment high dose intravenous methotrexate . For SER , adriamycin previously administer absolute neutrophil count platelet normal , administer without restriction study . Both group ( RER SER ) undergo maintenance chemotherapy thereafter , treatment duration 3 year 1st interim maintenance boys 2 year girl . For SER group , prophylactic radiotherapy do replace high dose intravenous methotrexate intensification intrathecal chemotherapy replace intrathecal methotrexate intrathecal cytarabine , methotrexate hydrocortisone .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Diagnosis 1 . Newly diagnose Bprecursor ALL meeting criterion 1.2 2 . Newly diagnose Bprecursor ALL previously treat steroid . 3 . Newly diagnose T cell ALL , exclude early Tcell precursor ( ETP ) leukemia 1.2 Initial WBC count 1. 1 year old 9 year old : WBC ≥ 50,000/μL 2. 10 year old 21 year old : Any WBC 3. 1 year old 21 year old : Any WBC Testicular leukemia CNS leukemia ( CNS3 ) 1 . Philadelphia chromosome ( + ) bcr/abl rearrangement ( + ) 2 . Chromosome &lt; 45 cytogenetics 3 . Induction failure ( Day 28 M3 marrow ( &gt; 25 % blast ) ) 4. ( 4:11 ) ( identify cytogenetics , FISH molecular study ) 5 . Early Tcell precursor leukemia 6 . Down syndrome ALL</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>